Exosome Diagnostics

OverviewSuggest Edit

Exosome Diagnostics develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The Company develops exosome-based diagnostics technology platform that harvests comprehensive and dynamic molecular information contained within exosomes from various fresh or frozen biofluids to deliver personalized healthcare to guide treatment decisions and in real-time along the entire patient care continuum.

TypePrivate
Founded2008
HQWaltham, MA, US
Websiteexosomedx.com

Latest Updates

Employees (est.) (Jul 2021)91(+3%)
Cybersecurity ratingBMore

Key People/Management at Exosome Diagnostics

John Boyce

John Boyce

CEO
William Kelly

William Kelly

CFO
Thomas McLain

Thomas McLain

COO
Johan Skog

Johan Skog

Chief Scientific Officer
Mikkel Noerholm

Mikkel Noerholm

Vice President Product Development
Raaj Venkatesan

Raaj Venkatesan

Vice President Regulatory Affairs and Quality
Show more

Exosome Diagnostics Office Locations

Exosome Diagnostics has offices in Waltham, Athens, Huntsville, Mobile and in 4 other locations
Waltham, MA, US (HQ)
266 2nd Ave #200
Athens, AL, US
101 Fitness Way #2300
Huntsville, AL, US
825 Adams St SE
Mobile, AL, US
6701 Airport Blvd Suite B135
Montgomery, AL, US
1722 Pine St #502
Opelika, AL, US
121 N 20th St #19
Show all (9)

Exosome Diagnostics Financials and Metrics

Summary Metrics

Founding Date

2008

Exosome Diagnostics total Funding

$112.1 m

Exosome Diagnostics latest funding size

$30 m

Time since last funding

4 years ago

Exosome Diagnostics investors

Exosome Diagnostics's latest funding round in July 2017 was reported to be $30 m. In total, Exosome Diagnostics has raised $112.1 m
Show all financial metrics

Exosome Diagnostics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Exosome Diagnostics Online and Social Media Presence

Embed Graph

Exosome Diagnostics News and Updates

Bio-Techne's Exosome Diagnostics Laboratory Announces CE-IVD Certification For ExoDx Prostate Test

MINNEAPOLIS, March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagnostic (IVD) version of the ExoDx™ Prostate test (EPI) kit enabling self-certification as...

Exosome Diagnostics and Therapeutics Market to See 39.9% Annual Growth Through 2023

WELLESLEY, Mass., June 10, 2019–The rising prevalence of cancer and infectious diseases are just two factors expected to shape the future of the exosome diagnostics and therapeutics market, according to a report by BCC Research, “Exosome Diagnostics and Therapeutics: Global Markets.”read more

Global Exosome Diagnostics and Therapeutics Markets Report 2019 - Current and Important Business Tool to Evaluate New Commercial Opportunities

DUBLIN, May 30, 2019 /PRNewswire/ -- The "Exosome Diagnostics and Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report represents a current and important business tool to evaluate new commercial opportunities in the exosome diagnostic,...

Exosome Diagnostics and Therapeutics: Global Markets

NEW YORK, May 28, 2019 /PRNewswire/ -- Report Scope: This report represents a current and important business tool to evaluate new commercial opportunities in the exosome diagnostic, therapeutic and research tool markets. The geographic scope of this study covers the U.S. and companies...

Latest Research On Lung Cancer Liquid Biopsy Market which Focuses on Top key Players like Biocept, Exosome Diagnostics, F. Hoffmann-La Roche, QIAGEN

The Global Lung Cancer Liquid Biopsy Market Report includes a comprehensive analysis of the present market. The report starts with the basic Lung Cancer Liquid Biopsy Market overview and then goes into each and every detail. Posted via Industry Today. Follow us on Twitter @IndustryToday

Exosome Diagnostics and Therapeutics Market Key Players (Active Networks) Are Codiak BioSciences, Evox Therapeutics, Exosome Diagnostics, Inc., HansaBioMed, NonosomiX, Inc

Exosome Diagnostics and Therapeutics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Exosome Diagnostics Frequently Asked Questions

  • When was Exosome Diagnostics founded?

    Exosome Diagnostics was founded in 2008.

  • Who are Exosome Diagnostics key executives?

    Exosome Diagnostics's key executives are John Boyce, William Kelly and Thomas McLain.

  • How many employees does Exosome Diagnostics have?

    Exosome Diagnostics has 91 employees.

  • Who are Exosome Diagnostics competitors?

    Competitors of Exosome Diagnostics include Evox Therapeutics, Genome Explorations and Flylife.

  • Where is Exosome Diagnostics headquarters?

    Exosome Diagnostics headquarters is located at 266 2nd Ave #200, Waltham.

  • Where are Exosome Diagnostics offices?

    Exosome Diagnostics has offices in Waltham, Athens, Huntsville, Mobile and in 4 other locations.

  • How many offices does Exosome Diagnostics have?

    Exosome Diagnostics has 9 offices.